| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 2mg | |||
| Other Sizes |
| Targets |
Sofosbuvir impurity F does not have a defined pharmacological target as it is an impurity standard, not a therapeutic agent. Its related compound, Sofosbuvir, targets the HCV NS5B RNA-dependent RNA polymerase, inhibiting viral RNA replication. The impurity itself is used for analytical purposes.
|
|---|---|
| ln Vitro |
In vitro activity of Sofosbuvir impurity F as a standalone compound has not been characterized, as it is not intended for biological studies. The related compound, Sofosbuvir, displays potent activity against hepatitis C virus by inhibiting HCV RNA replication.
|
| ln Vivo |
In vivo activity of Sofosbuvir impurity F as a standalone compound has not been characterized. The compound is used as an analytical standard and is not intended for in vivo studies. Its related compound, Sofosbuvir, is an approved anti-HCV drug with established in vivo efficacy.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not applicable to Sofosbuvir impurity F, as it is not a bioactive molecule. It is a chemical standard used for analytical method development and quality control.
|
| Cell Assay |
In vitro cell-based assays are not applicable to Sofosbuvir impurity F. The compound is used as a reference standard in analytical chemistry, not for cell-based studies.
|
| Animal Protocol |
In vivo animal studies are not applicable to Sofosbuvir impurity F. The compound is not intended for administration to animals. It is used exclusively as an analytical standard.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties of Sofosbuvir impurity F have not been characterized, as it is not a therapeutic agent. The compound is used as an analytical standard for quality control purposes. It is soluble in DMSO and should be stored at -20°C.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Sofosbuvir impurity F has not been characterized. The compound is intended for research use only and is not approved for human therapeutic applications.
|
| Additional Infomation |
Sofosbuvir impurity F is a research-grade chemical used as a reference standard for the analytical testing of Sofosbuvir. It is a diastereomer of Sofosbuvir and is also known as Sofosbuvir 3',5'-Bis-(S)-phosphate. The compound is supplied as a solid powder with a purity of ≥98%.
|
| Molecular Formula |
C34H45FN4O13P2
|
|---|---|
| Molecular Weight |
798.686034917831
|
| Exact Mass |
798.244
|
| CAS # |
1337482-17-3
|
| PubChem CID |
58463501
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
3.6
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
20
|
| Heavy Atom Count |
54
|
| Complexity |
1460
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
O=[P@@](N[C@@H](C)C(OC(C)C)=O)(OC[C@@H]1[C@@H](O[P@](OC2=CC=CC=C2)(N[C@@H](C)C(OC(C)C)=O)=O)[C@](F)(C)[C@H](N3C(NC(C=C3)=O)=O)O1)OC4=CC=CC=C4
|
| InChi Key |
WVORGVRHMQFKTN-ACVYKXDBSA-N
|
| InChi Code |
InChI=1S/C34H45FN4O13P2/c1-21(2)47-30(41)23(5)37-53(44,50-25-14-10-8-11-15-25)46-20-27-29(34(7,35)32(49-27)39-19-18-28(40)36-33(39)43)52-54(45,51-26-16-12-9-13-17-26)38-24(6)31(42)48-22(3)4/h8-19,21-24,27,29,32H,20H2,1-7H3,(H,37,44)(H,38,45)(H,36,40,43)/t23-,24-,27+,29+,32+,34+,53?,54?/m0/s1
|
| Chemical Name |
propan-2-yl (2S)-2-[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-4-methyl-3-[[[(2S)-1-oxo-1-propan-2-yloxypropan-2-yl]amino]-phenoxyphosphoryl]oxyoxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~125.2 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.13 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.13 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (3.13 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2521 mL | 6.2603 mL | 12.5205 mL | |
| 5 mM | 0.2504 mL | 1.2521 mL | 2.5041 mL | |
| 10 mM | 0.1252 mL | 0.6260 mL | 1.2521 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
